In IL-8 and Hs-CRP, inflammatory markers in colorectal cancer patients on chemotherapy, suggesting its potential as a complementary antitumor agent.


In the treatment outcomes of the patients with stroke by reducing the serum level of CRP, thus lowering the chances of developing ischemic attack and hemorrhagic stroke.